Could blood pressure drugs slow Parkinson's? major trial launches
NCT ID NCT07207057
First seen Nov 01, 2025
Summary
This large Phase 3 trial is testing whether two common drugs, telmisartan and terazosin, can slow the progression of Parkinson's disease. 1,200 participants will receive either a drug or a placebo for up to 36 months. The study uses a flexible design that can add new treatments over time, aiming to find effective therapies faster.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSONS DISEASE (PD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Clinical Ageing Research Unit
RECRUITINGNewcastle, NE4 5PL, United Kingdom
-
UCLH
RECRUITINGLondon, NW1 2PG, United Kingdom
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Telmisartan and terazosin (drugs repurposed for Parkinson's disease)
What this could lead to
If successful, this could provide new, safe treatments that slow the progression of Parkinson's disease, helping people maintain their abilities longer.
What could go wrong
This is an early-stage platform trial; the drugs may not slow progression. Side effects from the medications are possible, and results may take years to confirm.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.